Literature DB >> 8438619

Live oral vaccines against cholera: an update.

M M Levine1, J B Kaper.   

Abstract

One hundred years elapsed between the first (live, parenteral) cholera vaccine that entered clinical trials in 1885 and the field trials of two oral inactivated cholera vaccines undertaken in Bangladesh in the mid-1980s. The oral inactivated vaccines advanced the art by establishing, convincingly, that oral vaccines could protect (although multiple doses were required) and that (at least in adults) protection could last 3 years. Attenuated Vibrio cholerae O1 strain CVD 103-HgR (deleted of the cholera toxin A subunit gene and harbouring a gene encoding resistance to Hg++) constitutes another significant advance. This live oral vaccine is well tolerated and highly immunogenic in adults and children and highly protective (in adult volunteer challenge studies) following ingestion of of a single dose.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438619     DOI: 10.1016/0264-410x(93)90019-t

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

2.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

4.  Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Authors:  D A Sack; C O Tacket; M B Cohen; R B Sack; G A Losonsky; J Shimko; J P Nataro; R Edelman; M M Levine; R A Giannella; G Schiff; D Lang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Utility of rapid monoclonal antibody-based coagglutination test for direct detection of Vibrio cholerae O1 and/or O139 in stool samples.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

6.  Clinical impact of rapid in vitro susceptibility testing and bacterial identification.

Authors:  N H Renders; J A Kluytmans; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

7.  Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.

Authors:  H Kollaritsch; E Furer; C Herzog; G Wiedermann; J U Que; S J Cryz
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

Review 8.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

9.  Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

Authors:  S J Cryz; J U Que; M M Levine; G Wiedermann; H Kollaritsch
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

Review 10.  Helminth-Tuberculosis Co-infection: An Immunologic Perspective.

Authors:  Subash Babu; Thomas B Nutman
Journal:  Trends Immunol       Date:  2016-08-05       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.